A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)6796-6808
Number of pages13
JournalOncotarget
Volume8
Issue number4
DOIs
StatePublished - 2017

ASJC Scopus Subject Areas

  • Oncology

Keywords

  • Abiraterone
  • Androgen receptor
  • Androgen receptor mutation
  • CYP17 inhibitor
  • Prostate cancer

Fingerprint

Dive into the research topics of 'A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer'. Together they form a unique fingerprint.

Cite this